Skip to Content

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

We are planning system maintenance between Friday, Apr 18 at 9:00 PM CDT and Saturday, Apr 19 at 9:00 AM CDT. This will impact both web and offline transactions, including online orders, quotes, price and availability checks, and order status inquiries. We apologize for any inconvenience.

For important updates on recent policy changes, please click here for more details.

Merck
CN
  • Myoferlin is a novel exosomal protein and functional regulator of cancer-derived exosomes.

Myoferlin is a novel exosomal protein and functional regulator of cancer-derived exosomes.

Oncotarget (2016-11-16)
Arnaud Blomme, Karim Fahmy, Olivier Peulen, Brunella Costanza, Marie Fontaine, Ingrid Struman, Dominique Baiwir, Edwin de Pauw, Marc Thiry, Akeila Bellahcène, Vincent Castronovo, Andrei Turtoi
ABSTRACT

Exosomes are communication mediators participating in the intercellular exchange of proteins, metabolites and nucleic acids. Recent studies have demonstrated that exosomes are characterized by a unique proteomic composition that is distinct from the cellular one. The mechanisms responsible for determining the proteome content of the exosomes remain however obscure. In the current study we employ ultrastructural approach to validate a novel exosomal protein myoferlin. This is a multiple C2-domain containing protein, known for its conserved physiological function in endocytosis and vesicle fusion biology. Emerging studies demonstrate that myoferlin is frequently overexpressed in cancer, where it promotes cancer cell migration and invasion. Our data expand these findings by showing that myoferlin is a general component of cancer cell derived exosomes from different breast and pancreatic cancer cell lines. Using proteomic analysis, we demonstrate for the first time that myoferlin depletion in cancer cells leads to a significantly modulated exosomal protein load. Such myoferlin-depleted exosomes were also functionally deficient as shown by their reduced capacity to transfer nucleic acids to human endothelial cells (HUVEC). Beyond this, myoferlin-depleted cancer exosomes also had a significantly reduced ability to induce migration and proliferation of HUVEC. The present study highlights myoferlin as a new functional player in exosome biology, calling for novel strategies to target this emerging oncogene in human cancer.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-MYOF antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
25 mL
Estimated to ship on June 30, 2025
Details...
CN¥315.74
100 mL
Available to ship on April 18, 2025
Details...
CN¥1,156.67
Sigma-Aldrich
MISSION® pLKO.1-puro eGFP shRNA Control Plasmid DNA, shRNA sequence targeting eGFP
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
25 mL
Estimated to ship on June 30, 2025
Details...
CN¥315.74
100 mL
Available to ship on April 18, 2025
Details...
CN¥1,156.67